Tenax / Oxycyte: Will cooperation with Aurum be crowned with success?
The only truly valuable item in Tenax's assets is the research cooperation with Aurum Biosciences, the brain imaging company in Glasgow, Scotland, UK. This cooperation for the development of Oxycyte, a drug owned by Tenax, is the one race horse in the stable with the potential to compensate in the nearby future for all that clumsy destruction of share value that has taken place over the last decade. The Tenax-Aurum cooperation stipulates: “Aurum also signed a major research, development and commercialization deal with its US partner, Tenax Therapeutics, to develop Oxycyte, initially in the lead stroke indication. Tenax has granted Aurum full rights to develop and commercialize the product. Under the terms of this deal, the companies will share the benefits in stroke." However, in a strange relapse into secrecy, last week Tenax’s management has deleted this crucial information from its homepage. It’s somehow entertaining to see them trying to do that, in the times of Google and the Internet – it makes them appear a little bit worldly innocent, or old fashioned. Like little children, or foxy grannies!
As a Tenax shareholder simply go to "www.aurumbiosciences.com> Investor Information", and you will get all the deleted information first hand. Accurate knowledge of the Tenax-Aurum treaty is the basis for any investment decision. Shall I buy, shall I sell? This depends entirely on the question how one judges the success prospects for the Tenax-Aurum cooperation. Therefore, this treaty is an important asset that must figure prominently on Tenax’s homepage. This information cannot be deleted – especially not, after a clinical trial has been announced.
Well, then, how are the success prospects? Aurum Biosciences has announced that it will lead Oxycyte (drug supplied by Tenax) in Q1 2018 into a phase 2a trial in combination with MRI brain imaging technology (www.aurumbiosciences.com > News). Aurum is domiciled in Glasgow, Scotland, UK, and fully embedded in the University of Glasgow and the Queen Elizabeth University Hospital (QEUH) there. The University of Glasgow and its QEUH have launched a new research site for brain imaging, the Imaging Center of Excellence (ICE). The ICE is one of the world's most modern facilities. Its centerpiece is a brand-new £ 10 million MRI scanner, that was installed in November 2016. The arrival of this so called 7 Tesla MRI scanner was breaking news on BBC (www.bbc.com/news/uk-scotland-glasgow-west-38123803). Thanks to this supportive infrastructure, Aurum’s well designed research efforts are very likely to be crowned with success. This will be highly beneficial to the Tenax stock and all its dear shareholders because, as quoted above, the companies will share the benefits.
